RESUMO
Parasitic infections caused by Plasmodium, Trypanosoma, Leishmania, Toxoplasma and parasitic nematodes affect hundreds of millions of individuals worldwide and are the cause of significant mortality and morbidity, particularly in developing countries. These diseases also have an impact on individuals from developed countries; for example, some US troops in Iraq and Afghanistan have been infected with Leishmania. The annual mortality associated with parasitic infections is estimated to be 1.5 million deaths. The socioeconomic impact of the morbidity associated with parasitic infections is significant, and the development of new drugs, aimed at novel targets, is urgently needed to develop effective treatments for these diseases. The small-molecule inhibitors discussed in this review constitute useful tools with which to explore the relevance of kinase inhibition in inducing antiparasitic activity. The aim of recent target-based approaches used in the development of parasite kinase inhibitors is to identify novel antiparasitic agents with therapeutic potential.
Assuntos
Antiparasitários/farmacologia , Sistemas de Liberação de Medicamentos , Inibidores de Proteínas Quinases/farmacologia , Animais , Apicomplexa/efeitos dos fármacos , Apicomplexa/enzimologia , Apicomplexa/parasitologia , Humanos , Infecções por Nematoides/tratamento farmacológico , Infecções por Nematoides/enzimologia , Infecções por Nematoides/parasitologia , Doenças Parasitárias/tratamento farmacológico , Doenças Parasitárias/enzimologia , Doenças Parasitárias/parasitologia , Proteínas Quinases/efeitos dos fármacos , Trypanosoma/efeitos dos fármacos , Trypanosoma/enzimologia , Trypanosoma/parasitologiaRESUMO
The use of a multiplex mimetic assay led us to identify 1,4-dihydropyrimidines with potent and selective calcitonin receptor mimetic activity. Subsequent modification of the dihydropyrimidine scaffold led to a series of molecules that were efficacious in a neonatal mouse calvaria in vitro model. Dihydropyrimidine 5h, in particular, was identified as a calcitonin mimetic (EC(50)=6 microM), active in-vivo in the Weanling rat model when administered subcutaneously.